Literature DB >> 16776458

Improvements in treatment success rates with directly observed therapy in Rio de Janeiro City.

E C C Soares1, A G F Pacheco, F C Q Mello, B Durovni, R E Chaisson, S C Cavalcante.   

Abstract

SETTING: Rio de Janeiro City, Brazil.
OBJECTIVE: To evaluate the effect of directly observed therapy (DOT) on treatment success, by comparing the treatment success rates between patients treated under DOT with those who received self-administered therapy (SAT).
DESIGN: A longitudinal study in a cohort of tuberculosis (TB) patients. Of 9929 new pulmonary TB cases, 1190 (12%) were treated under DOT and 8739 (88%) under SAT. All patients received a three-drug regimen consisting of rifampicin (RMP), isoniazid (INH) and pyrazinamide for 2 months followed by 4 months of RMP and INH.
RESULTS: Patients under DOT were more likely to convert to sputum-negative at the end of the second month than those treated under SAT (86.3% vs. 61.9%, P < 0.001). DOT alone was significantly associated with successful treatment (OR 1.6, 95%CI 1.37-1.86, P < 0.001), even when controlled by sex, age and positive smear or culture at enrollment (OR 1.56, 95%CI 1.33-1.82, P < 0.001).
CONCLUSION: This pilot DOTS implementation phase showed that DOT is highly effective and feasible in a large urban centre of a developing country.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16776458

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  2 in total

1.  Community-randomized trial of enhanced DOTS for tuberculosis control in Rio de Janeiro, Brazil.

Authors:  S C Cavalcante; B Durovni; G L Barnes; F B A Souza; R F Silva; P F Barroso; C I Mohan; A Miller; J E Golub; R E Chaisson
Journal:  Int J Tuberc Lung Dis       Date:  2010-02       Impact factor: 2.373

2.  Health-service performance of TB treatment for indigenous and non-indigenous populations in Brazil: a cross-sectional study.

Authors:  Everton Ferreira Lemos; Aline Mara da Silva Alves; Giovana de Castro Oliveira; Marcella Paranhos Rodrigues; Natália Daiane Garoni Martins; Julio Croda
Journal:  BMC Health Serv Res       Date:  2014-05-23       Impact factor: 2.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.